卡波西肉瘤治疗研究新进展

doi:10.35541/cjd.20210303

Abstract

Abstract: 【Abstract】 The occurrence of Kaposi′s sarcoma （KS） is closely related to Kaposi′s sarcoma-associated herpesvirus （KSHV） infection of endothelial cells. KSHV infection can present as various types of KS, and clinical features, severity and prognosis differ among different types of KS. Classic KS is characterized by localized lesions and slow progression, AIDS-related KS and endemic KS are highly aggressive, and iatrogenic KS needs control of the primary disease during treatment. Therefore, individualized therapies should be developed according to the clinical classifications and characteristics of KS. This review summarizes treatment modalities of and research progress in KS.

Key words: Sarcoma, Kaposi, Drug therapy, Biological therapy, Antiretroviral therapy, highly active

Gao Yan, Wang Peng, Kang Xiaojing. Treatment of Kaposi′s sarcoma[J]. Chinese Journal of Dermatology, 2024, 57(1): 85-89.doi:10.35541/cjd.20210303

References ［32］

［1］	Dupin N. Update on oncogenesis and therapy for Kaposi sarcoma［J］. Curr Opin Oncol, 2020,32（2）:122⁃128. doi:10.1097/cco. 0000000000000601.
［2］	Odyakmaz Demirsoy E, Bayramgürler D, Çağlayan Ç, et al. Imiquimod 5% cream versus cryotherapy in classic Kaposi sarcoma［J］. J Cutan Med Surg, 2019,23（5）:488⁃495. doi: 10. 1177/1203475419847954.
［3］	Meseguer⁃Yebra C, Cardeñoso⁃Álvarez ME, Bordel⁃Gómez MT, et al. Successful treatment of classic Kaposi sarcoma with topical timolol: report of two cases［J］. Br J Dermatol, 2015,173（3）:860⁃862. doi:10.1111/bjd.13746.
［4］	Alcántara⁃Reifs CM, Salido⁃Vallejo R, Garnacho⁃Saucedo GM, et al. Classic Kaposi′s sarcoma treated with topical 0.5% timolol gel［J］. Dermatol Ther, 2016,29（5）:309⁃311. doi:10.1111/dth. 12381.
［5］	Sainz⁃Gaspar L, Suárez⁃Peñaranda JM , Pousa⁃Martínez M, et al. Topical timolol for treatment of penile Kaposi sarcoma in HIV⁃negative patient［J］. Dermatol Ther, 2017,30（5）. doi: 10.1111/dth.12519.
［6］	Abdelmaksoud A, Filoni A, Giudice G, et al. Classic and HIV⁃related Kaposi sarcoma treated with 0.1% topical timolol gel［J］. J Am Acad Dermatol, 2017,76（1）:153⁃155. doi: 10.1016/j.jaad. 2016.08.041.
［7］	Abdelmaksoud A, Filoni A, Giudice G, et al, Topical timolol for Kaposi sarcoma: an innovation［J］. Australas J Dermatol, 2018,59（4）:340⁃341. doi:10.1111/ajd.12817.
［8］	Delinikolas P, Patatoukas G, Kouloulias V, et al. A novel Hemi⁃Body Irradiation technique using electron beams （HBIe（⁃））［J］. 2018,46:16⁃24.
［9］	Platoni K, Diamantopoulos S, Dilvoi M, et al. First application of hemi⁃body electron beam irradiation for Kaposi sarcoma at the lower extremities［J］. J BUON, 2018,23（1）:268⁃272.
［10］	Kim SW, Kim C, Cho MS, et al. Clinical implementation of a wide⁃field electron arc technique with a scatterer for widespread Kaposi′s sarcoma in the distal extremities［J］. Sci Rep, 2020,10（1）:9693. doi: 10.1038/s41598⁃020⁃66846⁃5.
［11］	Tourlaki A, Germiniasi F, Rossi LC, et al. Paclitaxel as first⁃ or second⁃line treatment for HIV⁃negative Kaposi′s sarcoma: a retrospective study of 58 patients［J］. J Dermatolog Treat, 2020,31（2）:183⁃185. doi: 10.1080/09546634.2019.1590520.
［12］	Lebbe C, Garbe C, Stratigos AJ, et al. Diagnosis and treatment of Kaposi′s sarcoma: European consensus⁃based interdisciplinary guideline （EDF/EADO/EORTC）［J］. Eur J Cancer, 2019,114:117⁃127. doi: 10.1016/j.ejca.2018.12.036.
［13］	Du Q, Jiang G, Li S, et al. Docetaxel increases the risk of severe infections in the treatment of non⁃small cell lung cancer: a meta⁃analysis［J］. Oncoscience, 2018,5（7⁃8）:220⁃238. doi: 10.18632/oncoscience.444.
［14］	Hosokawa Y, Kato J, Hida T, et al. Docetaxel therapy for classic Kaposi′s sarcoma［J］. Asia Pac J Clin Oncol, 2019,15（3）:181⁃182. doi: 10.1111/ajco.13139.
［15］	Park MK, Cho H, Roh SW, et al. Cell type⁃specific interferon⁃γ⁃mediated antagonism of KSHV lytic replication［J］. Sci Rep, 2019,9（1）:2372. doi: 10.1038/s41598⁃019⁃38870⁃7.
［16］	Springgay LK, Fitzpatrick K, Park B, et al. Rhesus macaque rhadinovirus encodes a viral interferon regulatory factor to disrupt promyelocytic leukemia nuclear bodies and antagonize type I interferon signaling［J］. J Virol, 2019,93（6）:e02147⁃18. doi: 10.1128/JVI.02147⁃18.
［17］	Harris B, Walsh JL, Neciunaite R, et al. Ring a ring o′roses, a patient with Kaposi′s? Pazopanib, pazopanib, it might go away. Mediterranean （classic） Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy［J］. Clin Exp Dermatol, 2018,43（2）:234⁃236. doi: 10.1111/ced.13302.
［18］	Shaik F, Uldrick TS, Esterhuizen T, et al. Health⁃related quality of life in patients treated with antiretroviral therapy only versus chemotherapy and antiretroviral therapy for HIV⁃associated Kaposi sarcoma: a randomized control trial［J］. J Glob Oncol, 2018,4:1⁃9. doi: 10.1200/JGO.18.00105.
［19］	Busakhala NW, Waako PJ, Strother MR, et al. Randomized phase IIA trial of gemcitabine compared with bleomycin plus vincristine for treatment of Kaposi′s sarcoma in patients on combination antiretroviral therapy in Western Kenya［J］. J Glob Oncol, 2018,4:1⁃9. doi: 10.1200/JGO.17.00077.
［20］	Busakhala N, Kigen G, Waako P, et al. Three year survival among patients with aids⁃related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya［J］. Infect Agent Cancer, 2019,14:24. doi: 10.1186/s13027⁃019⁃0242⁃9.
［21］	Krown SE, Moser CB, MacPhail P, et al. Treatment of advanced AIDS⁃associated Kaposi sarcoma in resource⁃limited settings: a three⁃arm, open⁃label, randomised, non⁃inferiority trial［J］. Lancet, 2020,395（10231）:1195⁃1207. doi: 10.1016/S0140⁃6736（19）33222⁃2.
［22］	Reid EG, Suazo A, Lensing SY, et al. Pilot trial AMC⁃063: safety and efficacy of bortezomib in AIDS⁃associated Kaposi sarcoma［J］. Clin Cancer Res, 2020,26（3）:558⁃565. doi: 10.1158/ 1078⁃0432.CCR⁃19⁃1044.
［23］	Genovese G, Venegoni L, Fanoni D, et al. PD⁃L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi′s sarcoma［J］. J Eur Acad Dermatol Venereol, 2019,33（7）:e269⁃269e271. doi: 10.1111/jdv. 15543.
［24］	Galanina N, Goodman AM, Cohen PR, et al. Successful treatment of HIV⁃associated Kaposi sarcoma with immune checkpoint blockade［J］. Cancer Immunol Res, 2018,6（10）:1129⁃1135. doi: 10.1158/2326⁃6066.CIR⁃18⁃0121.
［25］	Uldrick TS, Gonçalves PH, Abdul⁃Hay M, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer⁃A phase 1 study［J］. JAMA Oncol, 2019,5（9）:1332⁃1339. doi: 10.1001/jamaoncol.2019.2244.
［26］	Chang XB, Zhu YX, Shi CX, et al. Mechanism of immuno⁃modulatory drugs′ action in the treatment of multiple myeloma［J］. Acta Biochim Biophys Sin （Shanghai）, 2014,46（3）:240⁃253. doi: 10.1093/abbs/gmt142.
［27］	Pourcher V, Desnoyer A, Assoumou L, et al. Phase II trial of lenalidomide in HIV⁃infected patients with previously treated Kaposi′s sarcoma: results of the ANRS 154 lenakap trial［J］. AIDS Res Hum Retroviruses, 2017,33（1）:1⁃10. doi: 10.1089/AID.2016.0069.
［28］	Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for symptomatic Kaposi′s sarcoma in people with and without HIV infection: a phase I/II study［J］. J Clin Oncol, 2016,34（34）:4125⁃4131. doi: 10.1200/JCO.2016.69.3812.
［29］	El⁃Mallawany NK, Villiera J, Kamiyango W, et al. Endemic Kaposi sarcoma in HIV⁃negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV⁃related disease［J］. Infect Agent Cancer, 2018,13:33. doi: 10.1186/s13027⁃018⁃0207⁃4.
［30］	Delyon J, Bizot A, Battistella M, et al. PD⁃1 blockade with nivolumab in endemic Kaposi sarcoma［J］. Ann Oncol, 2018,29（4）:1067⁃1069. doi: 10.1093/annonc/mdy006.
［31］	Delyon J, Rabate C, Euvrard S, et al. Management of Kaposi sarcoma after solid organ transplantation: a European retrospective study［J］. J Am Acad Dermatol, 2019,81（2）:448⁃455. doi: 10.1016/j.jaad.2019.03.028.
［32］	Yamashiro A, Awazawa R, Ohira A, et al. Successful treatment of iatrogenic Kaposi′s sarcoma with low⁃dose docetaxel therapy［J］. J Dermatol, 2018,45（4）:e96⁃96e97. doi: 10.1111/1346⁃8138. 14135.

[1]	Na Jun, Li Ruoyu, Zhong Shaomin, Yang Li, Wu Yan. Diagnosis and treatment of rosacea in the real world: a survey on the current status [J]. Chinese Journal of Dermatology, 2024, 57(2): 127-133.
[2]	Jia Weixue, Li Chengrang. Comparison of Chinese and international guidelines and consensus for the diagnosis and treatment of vitiligo [J]. Chinese Journal of Dermatology, 2023, 56(5): 471-475.
[3]	Jin Shiying, Shi Jinjun, Gao Qi, Chen Mei, Dong Zhengbang, Yan Qiao, Li Jijian, Wang Fei. High-frequency ultrasonography-assisted evaluation of treatment outcomes of erysipelas: a prospective controlled study [J]. Chinese Journal of Dermatology, 2023, 56(5): 434-438.
[4]	Peng Ying, Liu Yi. Medications for the treatment of acne [J]. Chinese Journal of Dermatology, 2023, 56(2): 173-176.
[5]	Hu Yebei, Song Xiuzu. Tranexamic acid for the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(5): 460-462.
[6]	Ding Yuwei, Qiao Jianjun, Fang Hong. Small-molecule targeted drugs and biological agents for alopecia areata [J]. Chinese Journal of Dermatology, 2022, 55(12): 1118-1121.
[7]	Ding Tiantian, Cui Baohong, Mi Shuhong, Zhang Yang, Zheng Hailin, Shi Jihai, Liu Weida. Comparison of drug susceptibility of and drug resistance mutations in fluconazole-resistant Candida albicans strains from superficial and deep infections [J]. Chinese Journal of Dermatology, 2022, 55(10): 874-878.
[8]	Lu Gaihui, Li Tao, Liu Xuewei. Effect of benzathine penicillin combined with ceftriaxone on the results of rapid plasma reagin circle card test/toluidine red unheated serum test in the treatment of early syphilis: a meta-analysis [J]. Chinese Journal of Dermatology, 2021, 54(6): 522-526.
[9]	Li Yan, Xu Wei, Gu Heng, Ju Mei, Duan Yiqun, Zeng Xianyu, Diao Qingchun, Ning Chunzhu, Li Linfeng. Acrivastine combined with loratadine in the treatment of chronic refractory urticaria: a multicenter, randomized controlled study [J]. Chinese Journal of Dermatology, 2020, 53(5): 319-323.
[10]	WANG Gang. Main adverse reactions in biological agents in dermatology and their strategies [J]. Chinese Journal of Dermatology, 2019, 52(2): 77-80.
[11]	Chen Xiufang, Xiao Rong, Zhan Yi, Zhang Guiying. Treatment of Rosai-Dorfman disease [J]. Chinese Journal of Dermatology, 2019, 52(10): 785-788.
[12]	Hu Yuqing, Zhang Jianzhong. Medications for atopic dermatitis [J]. Chinese Journal of Dermatology, 2019, 52(1): 57-60.
[13]	ZAN. Effects of turmeric volatile oil combined with cisplatin on the proliferation and apoptosis of a human cutaneous squamous cell carcinoma cell line A431 and their mechanisms [J]. Chinese Journal of Dermatology, 2018, 51(4): 294-298.
[14]	Xiao-Dong SUN zhihua leon liu runqiu Ping Li Jing Zhang xiao-jian CHEN lingling CHEN Li-Xia XIE. A tumor necrosis factor antagonist in the treatment of severe medicamentosa-like dermatitis induced by trichloroethylene: a clinical observation [J]. Chinese Journal of Dermatology, 2014, 47(4): 243-246.
[15]	. Efficacy comparison of uniform versus routine multidrug therapy for the treatment of multi-bacillary leprosy patients based on bacterial index and leprosy reactions [J]. Chinese Journal of Dermatology, 2012, 45(8): 553-556.

Treatment of Kaposi′s sarcoma

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［32］

Related Articles 15

Metrics

Comments

Recommended 10